Seòmar agus comataidhean

I refer the member to the answer to question S6W-10404 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

The Scottish Stroke Improvement Programme (SSIP) Lead conducts a review process and meets with all NHS boards to understand the provision of stroke services and create a local action plan to improve performance where needed.

We recognise that the Scottish Stroke Care Standards are challenging for the service and expect Stroke Managed Clinical Networks and Health Boards to work together to drive forward quality improvement programmes of work to achieve these.

Throughout the pandemic, a UK-wide approach to the procurement of therapeutics has been vital to allow the UK to have the buying power to secure significant numbers of therapeutics in a competitive global market. This approach has ensured patients across the UK have had equal access to safe and effective medicines.

Evusheld ® was developed and tested before the emergence of the Omicron variant, and the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) conditional marketing authorisation outlined some remaining questions, including how effective Evusheld ® is against Omicron and the duration of its effect against current circulating variants. As a result, there is currently no established supply arrangement for Evusheld ® in the UK. The UK Health Security Agency (UKHSA) is carrying out further testing on the effectiveness of Evusheld ® against the Omicron variants which involve “live virus” tests taking place in the lab (“in vitro”). These tests are important because they provide certainty of the effectiveness of Evusheld ® against circulating variants and avoid the risk of introducing new variants through viral mutations.

The Scottish Government continues to closely monitor the outcome of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence.

The following table provides a breakdown of the core activity undertaken at the National Eye Centre at NHS Golden Jubilee, by month, since it opened in November 2020 up to the end of June 2022.

This does not include activity undertaken in main theatres at the NHS Golden Jubilee University National Hospital in 2020-21 prior to the National Eye Centre opening, nor any activity carried out in the National Eye Centre as part of the current independent sector contracts.

I refer the member to the answer to question S6W-10433 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

Despite the continued and unprecedented challenges presented by the COVID-19 pandemic, the Scottish Stroke Improvement Programme report, published on 28 June, highlights areas where a high level of care is provided for stroke patients, including improvements in the number of patients who receive brain imagining within 12 hours of arrival to hospital.

We recognise that there are areas within stroke care that have proven particularly challenging and we are committed to continued improvement. We expect health boards to identify aspects of their stroke services which do not meet the Scottish Standards and to work to improve standards of care locally.

The number of thrombectomy procedures carried out at each stroke centre in the last year are:

West of Scotland: 16

East of Scotland: 17

North of Scotland: 31

The Scottish Government does not hold information about individual patients transfers.

We are not currently aware of any stroke unit closures.

The Scottish Stroke Improvement Programme team works closely with services and NHS boards to use learning from the Scottish Stroke Care Audit to support improvement across the whole stroke pathway, including timely access to thrombolysis.

For example, planning work is ongoing within NHS Greater Glasgow and Clyde to develop a telemedicine stroke service. This aims to introduce remote specialist assessment of hyperacute stroke patients out-of-hours at Glasgow Royal Infirmary and 24/7 at Royal Alexandra Hospital to improve overall door-to-needle (DTN) times for thrombolysis.

The Stroke Improvement Plan has been in place since its introduction in 2014 and has provided the framework for the provision of stroke care in Scotland.

The Stroke Improvement Plan emphasises the importance of the delivery of the stroke bundle, to ensure that all appropriate patients receive timely access to key interventions. The latest Scottish Stroke Improvement Programme annual report (published in June 2022 and available at: https://www.publichealthscotland.scot/publications/scottish-stroke-improvement-programme/scottish-stroke-improvement-programme-2022-national-report/ ) contains data collected in 2021. This demonstrated improvements in the initiation of aspirin therapy within one day (92% in 2021 v. 89% in 2020) and stroke patients receiving brain imaging within 12 hours (89% in 2021 v. 86% in 2020). Stroke bundle performance data for 2022 will be available in the 2023 national report, due to be published in June 2023.

In line with the Stroke Improvement Plan’s priority relating to the need for a skilled and knowledgeable workforce, in 2022 the Scottish Government has continued to support Stroke and TIA Assessment Training (STAT+), a standardised programme of thrombectomy education for trained healthcare professionals. We have provided funding to enable Chest Heart and Stroke Scotland to continue to deliver these education sessions to NHS Boards across Scotland to ensure increased knowledge, skills and management of thrombectomy patients. The delivery of this education package will support the ongoing rollout of a national thrombectomy service.